The therapeutic value of co-targeting ERK1 and Notch1 has yet to be demonstrated for RA but was shown effective in cancer in which Notch1 targeting enhanced ERK1 inhibitors’ efficacy in cancer patients [96]. Here, MAPK3 is linked to cancer.